Axogen Reports 23.1% Revenue Growth to $69.7 Million in Q2 2026

Axogen, Inc. reported significant financial results for the second quarter of 2026, with revenues reaching $69.7 million, a 23.1% increase from $56.7 million in the same period last year. For the first half of 2026, total revenues amounted to $131.2 million, up 24.7% from $105.2 million in the first half of 2025. The company’s gross profit for the quarter was $50.7 million, reflecting a gross margin of 72.7%, compared to 74.2% in the prior year. Despite the revenue growth, Axogen recorded a net loss of $1.5 million for the quarter, contrasting with a net income of $579,000 in Q2 2025. The loss for the first half of 2026 was $21.1 million, significantly higher than the $3.3 million loss reported in the same period last year.

The company’s operational metrics showed broad-based revenue growth across various markets, including Extremities and Oral Maxillofacial & Head and Neck, driven by increased account productivity and expanding sales force coverage. Axogen also highlighted the publication of a clinical study supporting its Axoguard Nerve Cap product and the initiation of a new study comparing its Avance Nerve Graft to traditional autografts. Additionally, Axogen acquired a minority stake in Trace Biosciences, which is expected to enhance its product offerings in nerve repair technologies.

In terms of financial position, Axogen's total assets increased to $304.9 million as of June 30, 2026, up from $221.7 million at the end of 2025. The company’s cash and cash equivalents rose to $94.6 million, bolstered by net proceeds from a public offering of common stock that generated $133.3 million. This capital was primarily used to pay off a credit facility, which was fully extinguished in January 2026. The company’s current ratio improved to 6.6x, indicating a strong liquidity position.

Axogen's total costs and expenses for the second quarter were $52.8 million, a 30.9% increase from $40.3 million in Q2 2025, driven by higher sales and marketing expenses and increased research and development costs. The company reported a significant increase in stock-based compensation expenses, reflecting anticipated performance-based awards due to sales growth. The increase in operational costs contributed to the net loss, despite the revenue growth.

Looking ahead, Axogen remains focused on expanding its presence in high-potential accounts and deepening the adoption of its nerve repair products. The company anticipates that its existing cash reserves and ongoing sales will support operations for at least the next twelve months. However, it also acknowledges potential risks from macroeconomic factors that could impact its business performance.